Kompanija Novo Nordisk je posvećena pravu društva na informacije, uz želju da one budu transparentne, jasne, razumljive i plasirane s poštovanjem.

Svrha kompanije Novo Nordisk je da pokreće  promene kako bi se pobedio dijabetes i druge ozbiljne hronične bolesti kao što su gojaznost, hemofilija i poremećaj rasta. To postižemo pionirskim naučnim dostignućima, širenjem pristupa našim lekovima i radom na prevenciji i izlečenju bolesti koje lečimo.

U oblasti komunikacija naš glavni cilj je stalno unapređenje znanja o tome šta je svrha naše kompanije, kao i informisanje društva u celini o ulozi koju imamo u oblasti zdravstva. Saradnja sa medijima je ključna za postizanje ovog cilja, uz poštovanje  važećih propisa.

S tim u vezi, ističemo da, kao farmaceutska kompanija koja se bavi lekovima koji se izdaju na recept, podležemo poštovanju propisa. Konkretno, proizvodi koje plasiramo na tržište ne mogu se oglašavati opštoj javnosti. Ne dovodeći u pitanje slobodu informisanja koja štiti medije, posvećeni smo poštovanju propisa i samim tim i ovog važnog ograničenja u vezi sa oglašavanjem lekova izdatih na lekarski recept.

At Novo Nordisk we are committed to society's right to information, showing an interest in this information being developed within a framework of transparency, and in a clear, understandable, and respectful manner.

Novo Nordisk's purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, bleeding, and growth disorders. We do this by pioneering scientific advances, expanding access to our medicines, and working to prevent and ultimately cure the diseases we treat.

The main objective of the Novo Nordisk Communication Department is the continuous improvement of knowledge of the purpose of our company, disseminating and conveying to society as a whole the role we play in the health and social field. Collaboration with the media is essential to achieve this objective and to do so while respecting all current regulations.

In relation to this point, we want to remind the media that, as a pharmaceutical company that markets prescription medications, we are subject to compliance with regulatory regulations. Specifically, none of the products marketed by this company can be promoted to the general public. Without prejudice to the freedom of information that protects the media, our commitment to regulations forces us to remember this important limitation regarding the promotion of drugs subject to medical prescription.